3 key details forecast a brighter future

On Monday, the drugmaker Moderna the results of a large-scale human trial evaluating the company’s coronavirus vaccine. It’s good news amid case counts hitting a : interim results show that the vaccine was 94.5 percent effective in preventing Covid-19.

That number puts it in league with the Pfizer vaccine, which claimed to be 90 percent effective in preventing infection. It’s another signal that there is a light at the end of this pandemic tunnel.

That 94.5 effectiveness number comes from interim results of Moderna’s Phase 3 clinical trial – the third and largest stage of human vaccine testing. This trial included more than 30,000 people who got the vaccine or a placebo, but these results come from a sample of 95 people who actually contracted Covid-19. Just five of those infected received the vaccine, the rest were in a placebo group.

The results were announced in a . The data has not been published in a peer-reviewed journal.

is a professor at the Emory Vaccine Cente and was not involved with the research. He comments that this percent could change — although the change may not be by very much.

“They can certainly change as bigger numbers come in,” Rao tells Inverse. “However, I would guess the efficacy would not drop below 80 percent.”

The results arrive just as the U.S. faces a seven-day average of more than per day. The vaccine can’t replace our efforts to control the loss of life in the coming months, but it does hint that there’s an end-date for the pandemic as we’re living experiencing it now.

“The vaccine is really the light at the end of the tunnel,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, on a call with reporters Monday.

Read More